KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Authors
Keywords
-
Journal
eLife
Volume 6, Issue -, Pages -
Publisher
eLife Sciences Organisation, Ltd.
Online
2017-02-01
DOI
10.7554/elife.18970
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
- (2016) Iok In Christine Chio et al. CELL
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
- (2016) John G Doench et al. NATURE BIOTECHNOLOGY
- CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions
- (2016) D. M. Munoz et al. Cancer Discovery
- Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting
- (2016) A. J. Aguirre et al. Cancer Discovery
- Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles
- (2016) E. Kim et al. Cancer Discovery
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†
- (2015) G. R. Blumenschein et al. ANNALS OF ONCOLOGY
- A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
- (2015) Frederick H. Wilson et al. CANCER CELL
- NRF2 regulates serine biosynthesis in non–small cell lung cancer
- (2015) Gina M DeNicola et al. NATURE GENETICS
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation
- (2014) John G Doench et al. NATURE BIOTECHNOLOGY
- Improved vectors and genome-wide libraries for CRISPR screening
- (2014) Neville E Sanjana et al. NATURE METHODS
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Easy quantitative assessment of genome editing by sequence trace decomposition
- (2014) Eva K. Brinkman et al. NUCLEIC ACIDS RESEARCH
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
- (2014) John D. Hayes et al. TRENDS IN BIOCHEMICAL SCIENCES
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System
- (2013) Baohui Chen et al. CELL
- Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer
- (2013) Charles M. Rudin et al. Journal of Thoracic Oncology
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition
- (2013) Cory M. Johannessen et al. NATURE
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- Genetic Screens in Human Cells Using the CRISPR-Cas9 System
- (2013) Tim Wang et al. SCIENCE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
- (2013) Joy Tang et al. Frontiers in Pharmacology
- Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
- (2012) Yoichiro Mitsuishi et al. CANCER CELL
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- (2012) Marcin Imielinski et al. CELL
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue
- (2012) Min Yuan et al. Nature Protocols
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
- (2011) Gina M. DeNicola et al. NATURE
- Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth
- (2010) P. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Phosphorylation of Nrf2 at Multiple Sites by MAP Kinases Has a Limited Contribution in Modulating the Nrf2-Dependent Antioxidant Response
- (2009) Zheng Sun et al. PLoS One
- Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth
- (2008) T. Ohta et al. CANCER RESEARCH
- Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
- (2008) X.-J. Wang et al. CARCINOGENESIS
- Genetic Alteration of Keap1 Confers Constitutive Nrf2 Activation and Resistance to Chemotherapy in Gallbladder Cancer
- (2008) Tatsuhiro Shibata et al. GASTROENTEROLOGY
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy
- (2008) T. Shibata et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now